AI Chat Paper
Note: Please note that the following content is generated by AMiner AI. SciOpen does not take any responsibility related to this content.
{{lang === 'zh_CN' ? '文章概述' : 'Summary'}}
{{lang === 'en_US' ? '中' : 'Eng'}}
Chat more with AI
Article Link
Collect
Submit Manuscript
Show Outline
Outline
Show full outline
Hide outline
Outline
Show full outline
Hide outline
Original Article

A santonin derivative, QX-6, alleviates ulcerative colitis by suppressing macrophage oxidative stress and inflammatory responses via modulation of ferroptosis-related signaling

Chuangmeng Xiaoa,Δ, Xinyi Xiec,Δ, Liqi Lvb,Δ, Jiangling Duanb, Xiaokun Zhangd, Yue Lib, Yanjun Wangb, Hongzhuan Chenb, Qingyan Sunf, Jinmei Jinb( ), Xin Luanb( ), Weidong Zhanga,b,c,e( )
State Key Laboratory for Quality Ensurance and Sustainable Use of Dao-di Herbs, Institute of Medicinal Plant Development, Chinese Academy of Medical Sciences & Peking Union Medical College, Beijing 100700, China
State Key Laboratory of Discovery and Utilization of Functional Components in Traditional Chinese Medicine, Shanghai Frontiers Science Center of TCM Chemical Biology, Institute of Interdisciplinary Integrative Medicine Research and Shuguang Hospital, Shanghai University of Traditional Chinese Medicine, Shanghai 201203, China
School of Pharmaceutical Sciences, Southern Medical University, Guangzhou 510515, China
School of Traditional Chinese Pharmacy, China Pharmaceutical University, Nanjing 210009, China
School of Pharmacy, Naval Medical University, Shanghai 200433, China
Shanghai Institute of Pharmaceutical Industry, China state Institute of Pharmaceutical Industry, Shanghai 201203, China

∆ These authors contributed equally to this work.

Show Author Information

Abstract

Ulcerative colitis (UC) is an inflammatory bowel disease primarily affecting the colon and rectum. Current therapies, including corticosteroids, immunosuppressants, biologics, and 5-aminosalicylates, remain limited by suboptimal efficacy, adverse effects, and drug resistance, highlighting the need for safer and more effective therapeutic agents. In the present study, we identified QX-6 as a novel small-molecule compound with potent anti-inflammatory activity. In lipopolysaccharide (LPS)-stimulated RAW264.7 macrophages and bone marrow-derived macrophages (BMDMs), QX-6 markedly reduced the expression of pro-inflammatory cytokines and reactive oxygen species (ROS) production. Multi-omics analyses further revealed significant enrichment of ferroptosis related pathways following QX-6 treatment. Consistently, QX-6 regulated the expression of ferroptosis-related proteins, including NRF2, HMOX1, GCLM, GPX4, FTL, and SLC40A1, while reducing ROS accumulation and lipid peroxidation and ameliorating ferroptosis-associated mitochondrial alterations in macrophages. Moreover, pharmacological induction of ferroptosis partially reversed the inhibitory effects of QX-6 on inflammatory cytokine expression and lipid peroxidation, further supporting the involvement of ferroptosis-related signaling in its anti-inflammatory activity. In vivo, QX-6 treatment significantly alleviated colon shortening in experimental models of UC, with the 120 mg·kg−1 dose showing the strongest protective effect, surpassing that of the positive control drug 5-aminosalicylic acid. Overall, these findings demonstrate that QX-6 exerts significant anti-inflammatory effects both in vitro and in vivo, and suggest that it may serve as a promising therapeutic candidate for UC.

References

【1】
【1】
 
 
Chinese Journal of Natural Medicines
Pages 1499-1508

{{item.num}}

Comments on this article

Go to comment

< Back to all reports

Review Status: {{reviewData.commendedNum}} Commended , {{reviewData.revisionRequiredNum}} Revision Required , {{reviewData.notCommendedNum}} Not Commended Under Peer Review

Review Comment

Close
Close
Cite this article:
Xiao C, Xie X, Lv L, et al. A santonin derivative, QX-6, alleviates ulcerative colitis by suppressing macrophage oxidative stress and inflammatory responses via modulation of ferroptosis-related signaling. Chinese Journal of Natural Medicines, 2026, 24(12): 1499-1508. https://doi.org/10.1016/S1875-5364(26)61236-8

4

Views

0

Crossref

0

Web of Science

0

Scopus

0

CSCD

Received: 24 March 2026
Revised: 21 July 2026
Accepted: 12 August 2026
Published: 20 December 2026
© 2026, China Pharmaceutical University.